These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 12727809

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice.
    Grippo PJ, Nowlin PS, Demeure MJ, Longnecker DS, Sandgren EP.
    Cancer Res; 2003 May 01; 63(9):2016-9. PubMed ID: 12727811
    [Abstract] [Full Text] [Related]

  • 3. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium.
    Lüttges J, Schlehe B, Menke MA, Vogel I, Henne-Bruns D, Klöppel G.
    Cancer; 1999 Apr 15; 85(8):1703-10. PubMed ID: 10223563
    [Abstract] [Full Text] [Related]

  • 4. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.
    Qian J, Niu J, Li M, Chiao PJ, Tsao MS.
    Cancer Res; 2005 Jun 15; 65(12):5045-53. PubMed ID: 15958547
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster.
    Cerny WL, Mangold KA, Scarpelli DG.
    Cancer Res; 1992 Aug 15; 52(16):4507-13. PubMed ID: 1643642
    [Abstract] [Full Text] [Related]

  • 7. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells.
    Agbunag C, Bar-Sagi D.
    Cancer Res; 2004 Aug 15; 64(16):5659-63. PubMed ID: 15313904
    [Abstract] [Full Text] [Related]

  • 8. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN.
    Siveke JT, Einwächter H, Sipos B, Lubeseder-Martellato C, Klöppel G, Schmid RM.
    Cancer Cell; 2007 Sep 15; 12(3):266-79. PubMed ID: 17785207
    [Abstract] [Full Text] [Related]

  • 9. DPC-4 (Smad-4) and K-ras gene mutations in biliary tract epithelium in children with anomalous pancreaticobiliary ductal union.
    Shimotake T, Aoi S, Tomiyama H, Iwai N.
    J Pediatr Surg; 2003 May 15; 38(5):694-7. PubMed ID: 12720172
    [Abstract] [Full Text] [Related]

  • 10. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.
    Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ.
    Cancer Res; 2007 Mar 01; 67(5):2098-106. PubMed ID: 17332339
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers.
    Laghi L, Orbetegli O, Bianchi P, Zerbi A, Di Carlo V, Boland CR, Malesci A.
    Oncogene; 2002 Jun 20; 21(27):4301-6. PubMed ID: 12082617
    [Abstract] [Full Text] [Related]

  • 14. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas.
    Ueda S, Fukamachi K, Matsuoka Y, Takasuka N, Takeshita F, Naito A, Iigo M, Alexander DB, Moore MA, Saito I, Ochiya T, Tsuda H.
    Carcinogenesis; 2006 Dec 20; 27(12):2497-510. PubMed ID: 16774944
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
    Wislez M, Spencer ML, Izzo JG, Juroske DM, Balhara K, Cody DD, Price RE, Hittelman WN, Wistuba II, Kurie JM.
    Cancer Res; 2005 Apr 15; 65(8):3226-35. PubMed ID: 15833854
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
    Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA.
    Mol Cancer Res; 2005 Jul 15; 3(7):413-23. PubMed ID: 16046552
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.